California Pharmas Spar Over Chinese Licensing

Law360, New York (March 30, 2007, 12:00 AM EDT) -- The legal wrangling between two California biopharmaceutical companies over the licensing of a cancer treatment in China has grown more intense with the filing of a counter-complaint.

Peregrine Pharmaceuticals Inc. filed suit against Cancer Therapeutics Laboratories in January in California Superior Court alleging breach of contract. The two companies entered into a joint licensing agreement in 1995 that allowed CTL to market and sell certain cancer treatments in China and Peregrine to market the same products everywhere else.

The treatment at issue is an antibody technology...
To view the full article, register now.